MYGN - ミリアド・ジェネティックス （Myriad Genetics Inc.）MYGNのニュース
Goldman Sachs Maintains Myriad Genetics Buy Recommendation 2023/05/25 02:37:35 24/7 Wall street
Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation.
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer 2023/05/24 20:05:00 GlobeNewswire
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE ®
Myriad Genetics Adds Folate Receptor Alpha to Precise Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer 2023/05/24 20:05:00 Wallstreet:Online
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds another companion diagnostic
Goldman Sachs Upgrades Myriad Genetics 2023/05/24 02:29:04 24/7 Wall street
Goldman Sachs has upgraded its outlook for Myriad Genetics to Buy.
Myriad Genetics rises as Goldman upgrades on growth potential 2023/05/23 19:43:42 Seeking Alpha
Myriad Genetics (MYGN) jumped ~13% Tuesday after Goldman Sachs upgraded it to Buy from Sell, citing its growth potential and outlook for gross margins. Read more here.
Investing in Myriad Genetics Inc. (MYGN) might be a great opportunity, but the stock is a bit overvalued 2022/11/30 12:08:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) closed Tuesday at $19.17 per share, up from $18.85 a day earlier. While Myriad Genetics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -29.13%, with highs and lows ranging from $28.45 to $15.38, whereas […]
Investing in Myriad Genetics Inc. (MYGN) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/17 16:00:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) marked $19.96 per share on Wednesday, down from a previous closing price of $20.88. While Myriad Genetics Inc. has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -33.20%, with highs and lows ranging from $30.29 to […]
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting 2022/11/14 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41 st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information 2022/11/10 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.
Why Shares of Myriad Genetics Dropped 24% This Week 2022/11/04 01:51:00 The Motley Fool
The genetic-testing company announced an acquisition and lowered its guidance.
Myriad Genetics, Inc. (MYGN) Q3 2022 - Earnings Call Transcript 2022/11/02 01:41:06 Seeking Alpha
Myriad Genetics, Inc. (NASDAQ:NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 01, 2022, 04:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO,…
Myriad Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2022/11/02 01:40:54 Seeking Alpha
The following slide deck was published by Myriad Genetics, Inc.
Myriad Genetics falls 19% after lowering full-year guidance, Q3 misses (NASDAQ:MYGN) 2022/11/01 15:52:16 Seeking Alpha
Myriad Genetics (MYGN) is down 19% in Tuesday morning trading after it narrowed its 2022 full-year guidance and its Q3 2022 financial results missed on the top and bottom lines.
Myriad Genetics Acquires Gateway Genomics as Q3 Revenues Drop 7 Percent, Miss Estimates 2022/11/01 14:51:05 GenomeWeb
The company reported $156.4 million in Q3 revenues compared to $167.3 million last year, and acquired consumer genetics firm Gateway Genomics.
Myriad Genetics Slashes FY22 Outlook As Q3 Results Miss Estimates; Stock Down 8% 2022/11/01 14:15:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue …